| 1 |
Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020-WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS [J]. Ultraschall Med, 2020, 41(5): 562-585.
|
| 2 |
Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells [J]. Ultrasound Med Biol, 2007, 33(2): 318-325.
|
| 3 |
Shunichi S, Hiroko I, Fuminori M, et al. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles [J]. Ultrasound Med Biol, 2009, 35(11): 1819-1827.
|
| 4 |
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects [J]. Radiology, 2014, 272(3): 635-654.
|
| 5 |
Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version) [J]. Ultraschall Med, 2018, 39(2): e2-e44.
|
| 6 |
American Colledge of Radiology. CEUS LI-RADS® v2017 [EB/OL]. (2017) [2022-05-30].
URL
|
| 7 |
Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS) [J]. Ultrasound Int Open, 2018, 4(1): E2-E15.
|
| 8 |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版) [J]. 中华肝脏病杂志, 2022, 30(4): 367-388.
|
| 9 |
American Colledge of Radiology. CEUS LI-RADS® [EB/OL]. (2016) [2022-05-30].
URL
|
| 10 |
Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The safety of SonoVue in abdominal applications: retrospective analysis of 23188 investigations [J]. Ultrasound Med Biol, 2006, 32(9): 1369-1375.
|
| 11 |
Tang C, Fang K, Guo Y, et al. Safety of sulfur hexafluoride microbubbles in sonography of abdominal and superficial organs: Retrospective analysis of 30,222 cases [J]. J Ultrasound Med, 2017, 36(3): 531-538.
|
| 12 |
Committee for Medicinal Products for Human Use (CHMP). Assessment report EMA/84084/2014. SonoVue. international non-properietary name: sulfur hexafluoride, NoProcedure. EMEA/H/C/000303/II/0025 [EB/OL]. (2014) [2022-05-30].
URL
|
| 13 |
Lee JY, Minami Y, Choi BI, et al. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid [J]. J Med Ultrasound, 2020, 28(2): 59-82.
|
| 14 |
Darge K, Papadopoulou F, Ntoulia A, et al. Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the society for pediatric radiology (SPR) and the international contrast ultrasound society (ICUS) [J]. Pediatr Radiol, 2013, 43(9): 1063-1073.
|
| 15 |
European Federation of Societies for Ultrasound in Medicine and Biology. Minimum training recommendations for the practice of medical ultrasound [EB/OL]. (2006-02) [2022-05-30].
URL
|
| 16 |
European Federation of Societies for Ultrasound in Medicine and Biology. Minimum training requirements for the practice of medical ultrasound in Europe [EB/OL]. (2009-04) [2022-05-30].
URL
|
| 17 |
European Federation of Societies for Ultrasound in Medicine and Biology. Minimum training requirements for the practice of medical ultrasound in Europe (Appendix 14) [EB/OL]. (2010) [2022-05-30].
URL
|